Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
5,800.00
+360.00 (6.62%)
At close: Jun 29, 2026
KOSDAQ:318160 Revenue
Cell Bio Human Tech Co.,Ltd had revenue of 12.75B KRW in the quarter ending March 31, 2026, with 53.80% growth. This brings the company's revenue in the last twelve months to 55.53B, up 80.57% year-over-year. In the year 2025, Cell Bio Human Tech Co.,Ltd had annual revenue of 51.07B with 79.69% growth.
Revenue (ttm)
55.53B
Revenue Growth
+80.57%
P/S Ratio
0.87
Revenue / Employee
740.34M
Employees
75
Market Cap
48.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.07B | 22.65B | 79.69% |
| Dec 31, 2024 | 28.42B | 1.09B | 4.01% |
| Dec 31, 2023 | 27.32B | -220.33M | -0.80% |
| Dec 31, 2022 | 27.54B | -7.62B | -21.66% |
| Dec 31, 2021 | 35.16B | 6.57B | 22.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guyoung Technology | 470.49B |
| Openbase | 251.47B |
| Korea Asset Investment Securities | 239.47B |
| Jeil Technos Co.,Ltd | 133.78B |
| Omnisystem | 90.20B |
| PIOLINK | 66.47B |
| POINT ENGINEERING | 33.37B |
| Russell | 30.53B |